drugset
drugset / Trial / NCT04522986

An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection

NCT04522986 ↗

Phase 1 Completed 6 enrolled Rohto Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.

Timeline

Start
2020-08-21
Primary completion
2021-02-02
Completion
2021-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ADR-001 Cell therapy 1e+08 cells Intravenous

Indications

COVID-19